VUEWAY®
(gadopiclenol)
VUEWAY® is the new Bracco contrast-agent, with the highest relaxivity* of all GBCAs today combined with high stability,4 making effective MRI contrast enhancement possible at half the gadolinium dose.**1-3
*Together with Elucirem® (gadopiclenol)
**Half the gadolinium dose compared to gadobutrol at a standard recommended gadolinium dose of 0.1 mmol/kg in approved indications.
Molecule and Physiochemical properties
The chemical structure of gadopiclenol allows for a high r1 relaxivity by influencing three main parameters: inner and outer sphere coordination sites and tumbling rate.1,4
The large molecule size leads to a lower tumbling rate, which is the reason for higher relaxivity compared to previously approved GBCAs.
Relaxivity (r1 or r2) is the extent to which a contrast agent can increase the relaxation rate of tissue water (1/T1 or 1/T2).
Inner sphere coordination
The structure of gadopiclenol permits the coordination of two water molecules in the inner sphere (q=2) versus one water molecule for the other GBCAs (q=1)
The inner-sphere relaxivity is directly proportional to the number of water molecules coordinated with the gadolinium ion. Thus, q=2 in gadopiclenol contributes to increase the relaxivity
Tumbling rate
Gadopiclenol has a large molecule size due to 3 hydrophilic polyalcohol pendant arms, which reduce rotational diffusion and leads to a lower tumbling rate.
Outer sphere coordination
Gadopiclenol was designed with 3 hydrophilic polyalcohol side chains to increase the number of water molecules bound through the outer coordination sphere mechanism.
Indications
VUEWAY® is indicated in adults and children from birth for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualization of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:
- The brain, spine, and associated tissues of the central nervous system (CNS)
- The liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system
It should be used only when diagnostic information is essential and not available with unenhanced MRI.1
VUEWAY®, developed with Bracco’s scientific expertise, reflects our commitment to advancing MRI by delivering innovative contrast agents designed to shape the future of prevention and improve patients’ lives. Watch this video to see how VUEWAY® is redefining the MRI contrast experience.
References
1. VUEWAY® (gadopiclenol) solution for injection, 485.1 mg/mL. Product Monograph. BRACCO IMAGING Canada. Montreal, QC; April 2026.
2. Loevner L, et al. Invest Radiol. 2023;1;58(5):307-313.
3. Kuhl C, et al. Radiol. 2023;308(1).
4. Robic C, et al. Invest Radiol. 2019;54:475-484.
5. Lancelot E, et al. Invest Radiol. 2020;55(9):578-588.
6. Spinazzi et al., Invest Radiol. 2025, 10.1097/RLI.0000000000001144.
7. Jurkiewicz E, et al. Invest Radiol. 2022;1;57(8):510-516.
8. Loevner LA, et al. Invest Radiol 2023;58: 307–313.
9. Brünjes R, Hofmann T. Water Research 2020;182:115966.
High relaxivity
Relaxivity (r1 or r2) at given concentration is the extent to which a contrast agent can increase the relaxation rate of tissue water (1/T1 or 1/T2). VUEWAY® has the highest relaxivity of all macrocyclic GBCAs approved today .*4 VUEWAY® demonstrates 2.5-to-3.5 fold higher relaxivity than all mGBCAs approved today at all relevant MRI field strengths.*4
*Together with Elucirem (gadopiclenol)
Half dose
VUEWAY® provides higher qualitative contrast enhancement at half the gadolinium dose.*2,3 The potential benefits of injecting half gadolinium are particularly important for vulnerable patient populations due to reduction of cumulative gadolinium dose: 3,5,6
* Half the gadolinium dose compared to gadobutrol at a standard recommended gadolinium dose of 0.1 mmol/kg in approved indications.
Safety profile
VUEWAY® has a pharmacokinetic profile comparable to that of other macrocyclic gadolinium chelates.1
In clinical trials VUEWAY® (gadopiclenol) has shown a good safety profile in adults and children (0–17 yrs).1-3,6,7
From Spinazzi et al., "Safety of Gadopiclenol After Its First Year of Clinical Use", (Invest Radiol. 2025):
- Post-marketing surveillance – Data after 1 year of routine clinical use on 882,550 gadopiclenol applications.
- Results:
- Low adverse event (AE) rates reported (0.0036; 1/27,580)
- Types of AEs comparable to the AEs reported with other GBCAs
- No Weber effect* reported so far
*The Weber effect states that the number of reported adverse reactions to a drug tends to peak during the second year after the drug is introduced to the market, and then declines steadily thereafter, despite continued widespread use of the drug.
References
1. VUEWAY® (gadopiclenol) solution for injection, 485.1 mg/mL. Product Monograph. BRACCO IMAGING Canada. Montreal, QC; April 2026.
2. Loevner L, et al. Invest Radiol. 2023;1;58(5):307-313.
3. Kuhl C, et al. Radiol. 2023;308(1).
4. Robic C, et al. Invest Radiol. 2019;54:475-484.
5. Lancelot E, et al. Invest Radiol. 2020;55(9):578-588.
6. Spinazzi et al., Invest Radiol. 2025, 10.1097/RLI.0000000000001144.
7. Jurkiewicz E, et al. Invest Radiol. 2022;1;57(8):510-516.
8. Loevner LA, et al. Invest Radiol 2023;58: 307–313.
9. Brünjes R, Hofmann T. Water Research 2020;182:115966.
At Bracco, we put sustainability at the core of our growth. VUEWAY® is a clear example of this commitment - its efficient molecular design leads to high relaxivity, delivering an enhanced MRI experience with reduced gadolinium exposure.
What benefits does VUEWAY® bring to patients and the environment?
- For patients and providers: Effective imaging at a 50% lower gadolinium dose compared to the recommended dose of other macrocyclic GBCAs8 - supporting ALARA principle application in daily practice.
- For the planet: Up to 9.5 tonnes of gadolinium potentially saved per year9, without compromising diagnostic confidence.
Discover how VUEWAY® can help you achieve your sustainability goals.
|
VUEWAY: An enhanced MRI experience with reduced gadolinium |
DOWNLOAD THE LEAFLET | |||
References
1. VUEWAY® (gadopiclenol) solution for injection, 485.1 mg/mL. Product Monograph. BRACCO IMAGING Canada. Montreal, QC; April 2026.
2. Loevner L, et al. Invest Radiol. 2023;1;58(5):307-313.
3. Kuhl C, et al. Radiol. 2023;308(1).
4. Robic C, et al. Invest Radiol. 2019;54:475-484.
5. Lancelot E, et al. Invest Radiol. 2020;55(9):578-588.
6. Spinazzi et al., Invest Radiol. 2025, 10.1097/RLI.0000000000001144.
7. Jurkiewicz E, et al. Invest Radiol. 2022;1;57(8):510-516.
8. Loevner LA, et al. Invest Radiol 2023;58: 307–313.
9. Brünjes R, Hofmann T. Water Research 2020;182:115966.
Two pivotal Phase III crossover studies comparing VUEWAY® at 0.05 mmol/kg and gadobutrol at 0.1 mmol/kg.2,3
The Picture study2
In the CNS study, primary endpoints were met: Demonstrating that VUEWAY® provides non-inferior, or comparable lesion visualization at half the gadolinium dose (0.05 mmol/kg) vs. gadobutrol.
*All images shown are representative images from referenced studies. Individual results may vary.
†Presented studies in their primary outcomes proved non-inferiority of VUEWAY® (0.05 mmol/kg) in half gadolinium dose compared to gadobutrol (0.1 mmol/kg) in full gadolinium dose.
‡From Phase III PICTURE Clinical Trial of MRI in the CNS: Study GDX-44-010. Data on file.
The Promise study3
In the Body study (PROMISE), primary endpoints were met: Superiority of VUEWAY® at 0.05 mmol/kg to unenhanced MRI across lesion visualization criteria.
MRI of the Body - A 66-year-old male patient with hepatocellular cancer‡
Contrast-enhanced MRI of the liver after administration of gadopiclenol (0.05 mmol/kg) and gadobutrol (0.1 mmol/kg). Axial three-dimensional T1-weighted dynamic contrast-enhanced MRI scans during the (A, D) arterial, (B, E) portal venous, and (C, F) delayed phases
MRI of the Breast - 68-year-old female patient with left breast adenocarcinoma
*All images shown are representative images from referenced studies. Individual results may vary.
†Presented studies in their primary outcomes proved non-inferiority of VUEWAY® (0.05 mmol/kg) in half gadolinium dose compared to gadobutrol (0.1 mmol/kg) in full gadolinium dose.
‡From Phase III PROMISE Clinical Trial of MRI in the Body: Study GDX-44-011. Data on file.
References
1. VUEWAY® (gadopiclenol) solution for injection, 485.1 mg/mL. Product Monograph. BRACCO IMAGING Canada. Montreal, QC; April 2026.
2. Loevner L, et al. Invest Radiol. 2023;1;58(5):307-313.
3. Kuhl C, et al. Radiol. 2023;308(1).
4. Robic C, et al. Invest Radiol. 2019;54:475-484.
5. Lancelot E, et al. Invest Radiol. 2020;55(9):578-588.
6. Spinazzi et al., Invest Radiol. 2025, 10.1097/RLI.0000000000001144.
7. Jurkiewicz E, et al. Invest Radiol. 2022;1;57(8):510-516.
8. Loevner LA, et al. Invest Radiol 2023;58: 307–313.
9. Brünjes R, Hofmann T. Water Research 2020;182:115966.
Watch expert insights from Daniela Bernardi and Francesco Sardanelli where they share their clinical perspectives on the role of Vueway® in breast MRI and the added value of using a safe GBCA with high relaxivity at half the gadolinium dose**
**Half the gadolinium dose compared to gadobutrol at a standard recommended Gd dose of 0.1 mmol/kg in approved indications.
*from 10 to 140 kg
VUEWAY®
0.5 M
Volume (ml)
Quantity (mmol)
Macrocyclic
GBCA
1.0 M
Volume (ml)
Quantity (mmol)
Macrocyclic
GBCA
0.5 M
Volume (ml)
Quantity (mmol)
| VUEWAY® Summary of Product Characteristics | 04/24/2026 | Download |